{"id":"NCT01626456","sponsor":"Alkermes, Inc.","briefTitle":"A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","officialTitle":"A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2012-06-22","resultsPosted":"2016-10-27","lastUpdate":"2018-09-25"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 9072, Low","otherNames":[]},{"type":"DRUG","name":"ALKS 9072, High","otherNames":[]}],"arms":[{"label":"ALKS 9072, Low","type":"EXPERIMENTAL"},{"label":"ALKS 9072, High","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.","primaryOutcome":{"measure":"Number of Subjects With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"52 weeks","effectByArm":[{"arm":"ALKS 9072, Low","deltaMin":51,"sd":null},{"arm":"ALKS 9072, High","deltaMin":190,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":82,"countries":["United States","Bulgaria","Malaysia","Philippines","Romania","Russia","South Korea","Ukraine"]},"refs":{"pmids":["28350572","33761928","32841554","30109845","29941057"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":110},"commonTop":["Insomnia","Weight increased","Headache"]}}